Previous Close | 1.8900 |
Open | 0.8500 |
Bid | 1.5500 |
Ask | 1.9000 |
Strike | 3.00 |
Expire Date | 2024-01-19 |
Day's Range | 1.8900 - 1.8900 |
Contract Range | N/A |
Volume | |
Open Interest | 134 |
Urges Shareholders to Vote “AGAINST” Sarissa’s Proposals on the WHITE Proxy Card Highlights Significant Changes Implemented Over Last 18 Months – New Strategy, New Leadership Team and Significantly Refreshed Board; Transformation Underway with Strong Early Progress Advancing Geographic Expansion and Operational and Financial Excellence Underscores Sarissa’s Misguided Proxy Contest – Sarissa Has No Plan or New Ideas and Slate is Underqualified Company Launches www.voteamarin.com, Featuring Videos
Marks 7th Regulatory Approval for VASCEPA®/VAZKEPA® Franchise in Key International Markets Since 2022DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 27, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Medsafe in New Zealand has granted approval to VAZKEPA (icosapent ethyl) to reduce the risk of cardiovascular (CV) events in adult statin-treated patients with high CV risk with elevated triglycerides. Cardiovascular disease is a significant health issue for people li
DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 27, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Karim Mikhail, Amarin’s president and chief executive officer, is scheduled to participate at the SVB Securities Global Biopharma Conference. SVB Securities Global Biopharma Conference (February 13-16th, 2023; Virtual) Date/Time: February 14, 2023 10:40 a.m. ET Webcast: https://wsw.com/webcast/svb8/register.aspx?conf=svb8&page=amrn&url=https://wsw.com/webcast/svb8/am